BGPartner advised on one of the largest financing rounds
04. February 2022
BGPartner advised on one of the largest financing rounds in Switzerland, according to the Swiss Venture Capital Report 2022.
BGPartner is proud to have advised on one of the largest financing rounds in Switzerland: according to the Swiss Venture Capital Report 2022, the CHF 100 million investment in Numab Therapeutics Ltd ranks among the top 20 (rank 5) of the largest financing rounds in 2021.
In this transaction HBM Healthcare Investments Ltd and Novo Holdings A/S, as co-lead-investors, together with other investors including Forbion and Black Rock, successfully closed in 2021 an investment in Numab Therapeutics Ltd’s series C financing round.
Numab Therapeutics Ltd is a clinical stage biopharmaceutical company developing next-generation multi-specific antibody-based immunotherapies for cancer and inflammation.
BGPartner assisted HBM Healthcare Investments Ltd and Novo Holdings A/S in the negotiations and advised them on all Swiss legal matters with regard to this series c financing round. The team was led by Oliver Gnehm (Partner) and further consisted of Olivier Bula (Partner), Victoria Marty (Associate), Thomas Gysin (Senior Associate) and Fabiola Anthamatten (Managing Associate).
BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.